



Cue Biopharma to Present at the World Vaccine & Immunotherapy Congress

December 2, 2019

Presentation Highlights Recent Platform Development Providing the Potential to Readily Exchange T cell Epitopes to Target Diverse T cell Populations

CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- [Cue Biopharma, Inc.](#) (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today Dr. John Ross, Ph.D., vice president of protein therapeutics, will give a presentation highlighting the potential of the company's proprietary therapeutic platform Immuno-STAT™ (*Selective Targeting and Alteration of T cells*) and associated Cue Biopharma Neo-STAT™ platform development at the [World Vaccine & Immunotherapy Congress](#) taking place on Dec. 2-5, 2019 at the San Francisco Airport Marriott Waterfront.

Presentation Details

Title: [Immuno-STAT™ and Neo-STAT™ – Therapeutic platforms for the selective modulation of antigen-specific T cells](#)

Presenter: [John Ross, Ph.D., vice president, protein therapeutics](#)

Date & Time: Dec. 5 at 12:10 p.m. PT

"This presentation highlights the core strength and therapeutic potential of our Immuno-STAT platform to selectively target and drug antigen-specific T cells directly in the patient," said Dr. Anish Suri, Ph.D. president and chief scientific officer of Cue Biopharma. "Furthermore, the evolution of the Neo-STAT platform may allow for the generation of therapeutic molecules that can incorporate diverse T cell epitopes, including peptides bearing post-translational modifications and those derived from tumor neo-antigens, thereby broadening our reach to novel opportunities in personalized immunotherapy. The Neo-STAT platform exploits chemical attachment of T cell epitopes to stabilized HLA molecules, along with desired co-stimulatory signals, to generate polyspecific therapeutic molecules for activating tumor-specific T cells directly in the patient."

"CUE-101, our lead clinical candidate, is exemplary of the Immuno-STAT platform and is currently being dosed in patients suffering from recurrent and metastatic head and neck cancer," said Daniel Passeri, chief executive officer of Cue Biopharma. "Through the deployment of the Cue Biopharma Neo-STAT platform, we can potentially expand patient reach and exploit significant time and cost-related efficiencies."

About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The company's proprietary Immuno-STAT™ (*Selective Targeting and Alteration of T cells*) platform is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology treatments.

For more information, visit www.cuebio.com and follow us on Twitter <https://twitter.com/CueBiopharma>.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug development efforts, including study results, our expectations regarding regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; our ability to secure required U.S. Food and Drug Administration ("FDA") or other governmental approvals for our product candidates and the breadth of any approved indication; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; our reliance on licensors, collaborations and strategic alliances; our ability to obtain adequate financing to fund our business operations in the future; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to

time, whether as a result of new information, future developments or otherwise.

Investor Contact

Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com

Media Contact

Alison Chen
LifeSci Public Relations
achen@lifescipublicrelations.com



Source: Cue Biopharma, Inc.